New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
Stable profits, low leverage to keep credit profiles comfortable
This license will enable Abbott to enhance access to this novel therapy to more patients across India
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
Subscribe To Our Newsletter & Stay Updated
